Cleared Traditional

K982061 - STC COCAINE METABOLITE MICRO-PLATE EIA (ORASURE DEVICE)

K982061 is an FDA 510(k) clearance for STC COCAINE METABOLITE MICRO-PLATE EIA ..., manufactured by OraSure Technologies, Inc.. The device is a Class 2 Toxicology device with product code DIO cleared through the Traditional 510(k) pathway after a 82-day FDA review.

K982061 · OraSure Technologies, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1998
Decision
82d
Days
Class 2
Risk

K982061 is an FDA 510(k) clearance for the STC COCAINE METABOLITE MICRO-PLATE EIA (ORASURE DEVICE). Classified as Enzyme Immunoassay, Cocaine And Cocaine Metabolites (product code DIO), Class II - Special Controls.

Submitted by OraSure Technologies, Inc. (Bethlehem, US). The FDA issued a Cleared decision on August 25, 1998 after a review of 82 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3250 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all OraSure Technologies, Inc. devices

FDA 510(k) Submission Details - K982061

510(k) Number K982061 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 04, 1998
Decision Date August 25, 1998
Days to Decision 82 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
5d faster than avg
Panel avg: 87d · This submission: 82d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DIO Device Classification - Class 2, Special Controls

Product Code DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites

All 116
Devices cleared under the same product code (DIO) and FDA review panel - the closest regulatory comparables to K982061.
AUTO-LYTE COCAINE METABOLITE EIA, MODEL # 1222U
K982759 · OraSure Technologies, Inc. · Nov 1998
DBEST COCAINE TEST KIT
K983191 · Ameritek, Inc. · Nov 1998
ONTRAK TESTCUP-ER
K983388 · Roche Diagnostic Systems, Inc. · Nov 1998
MICRO-STRIP FOR COCAINE METABOLITES
K981388 · Microdiagnostics, Inc. · May 1998
MECTEST
K973986 · Meco Industries · Apr 1998
DRUG CHECK
K980153 · Texas Immunology, Inc. · Mar 1998